DE69937368T2 - Nachweis von erkrankungen der nieren und behandlung - Google Patents
Nachweis von erkrankungen der nieren und behandlung Download PDFInfo
- Publication number
- DE69937368T2 DE69937368T2 DE69937368T DE69937368T DE69937368T2 DE 69937368 T2 DE69937368 T2 DE 69937368T2 DE 69937368 T DE69937368 T DE 69937368T DE 69937368 T DE69937368 T DE 69937368T DE 69937368 T2 DE69937368 T2 DE 69937368T2
- Authority
- DE
- Germany
- Prior art keywords
- disease
- protein
- albumin
- modified
- urine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000017169 kidney disease Diseases 0.000 title claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 87
- 210000002700 urine Anatomy 0.000 claims abstract description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 69
- 201000010099 disease Diseases 0.000 claims abstract description 57
- 102000035118 modified proteins Human genes 0.000 claims abstract description 29
- 108091005573 modified proteins Proteins 0.000 claims abstract description 29
- 102000009027 Albumins Human genes 0.000 claims description 178
- 108010088751 Albumins Proteins 0.000 claims description 178
- 239000000523 sample Substances 0.000 claims description 46
- 238000003127 radioimmunoassay Methods 0.000 claims description 42
- 206010012601 diabetes mellitus Diseases 0.000 claims description 32
- 210000003734 kidney Anatomy 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 20
- 238000004587 chromatography analysis Methods 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 208000022461 Glomerular disease Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 102000005686 Serum Globulins Human genes 0.000 claims description 6
- 108010045362 Serum Globulins Proteins 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 5
- 201000010064 diabetes insipidus Diseases 0.000 claims description 5
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 208000024985 Alport syndrome Diseases 0.000 claims description 4
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 4
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims description 4
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 208000024720 Fabry Disease Diseases 0.000 claims description 4
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 206010024229 Leprosy Diseases 0.000 claims description 4
- 208000000175 Nail-Patella Syndrome Diseases 0.000 claims description 4
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 206010037596 Pyelonephritis Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 208000012998 acute renal failure Diseases 0.000 claims description 4
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 4
- 238000005227 gel permeation chromatography Methods 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 210000000585 glomerular basement membrane Anatomy 0.000 claims description 4
- 208000003215 hereditary nephritis Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000002483 medication Methods 0.000 claims description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 4
- 231100000855 membranous nephropathy Toxicity 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
- 201000011461 pre-eclampsia Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010000599 Acromegaly Diseases 0.000 claims description 3
- 108010068307 Alpha-Globulins Proteins 0.000 claims description 3
- 102000002572 Alpha-Globulins Human genes 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 3
- 102000006734 Beta-Globulins Human genes 0.000 claims description 3
- 108010087504 Beta-Globulins Proteins 0.000 claims description 3
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 208000017701 Endocrine disease Diseases 0.000 claims description 3
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 3
- 108010015776 Glucose oxidase Proteins 0.000 claims description 3
- 239000004366 Glucose oxidase Substances 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 102100030856 Myoglobin Human genes 0.000 claims description 3
- 108010062374 Myoglobin Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 108010061952 Orosomucoid Proteins 0.000 claims description 3
- 102000012404 Orosomucoid Human genes 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000002774 Paraproteinemias Diseases 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 102100038803 Somatotropin Human genes 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 238000012084 abdominal surgery Methods 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 230000037005 anaesthesia Effects 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 208000030172 endocrine system disease Diseases 0.000 claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 claims description 3
- 238000001030 gas--liquid chromatography Methods 0.000 claims description 3
- 229940116332 glucose oxidase Drugs 0.000 claims description 3
- 235000019420 glucose oxidase Nutrition 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 238000001155 isoelectric focusing Methods 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 230000002956 necrotizing effect Effects 0.000 claims description 3
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 3
- 238000004816 paper chromatography Methods 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 229960001639 penicillamine Drugs 0.000 claims description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 238000004809 thin layer chromatography Methods 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 238000007631 vascular surgery Methods 0.000 claims description 3
- 238000007693 zone electrophoresis Methods 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 238000004810 partition chromatography Methods 0.000 claims description 2
- 101001026869 Mus musculus F-box/LRR-repeat protein 3 Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 82
- 210000003712 lysosome Anatomy 0.000 description 34
- 230000001868 lysosomic effect Effects 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000002132 lysosomal effect Effects 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000029142 excretion Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 208000033679 diabetic kidney disease Diseases 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 206010027525 Microalbuminuria Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 230000008427 tissue turnover Effects 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000006674 lysosomal degradation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP784398 | 1998-12-21 | ||
| AUPP7843A AUPP784398A0 (en) | 1998-12-21 | 1998-12-21 | Kidney disease detection and treatment |
| US09/415,217 US6447989B1 (en) | 1998-12-21 | 1999-10-12 | Kidney disease detection and treatment |
| US415217 | 1999-10-12 | ||
| PCT/IB1999/002029 WO2000037944A1 (en) | 1998-12-21 | 1999-12-20 | Kidney disease detection and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69937368D1 DE69937368D1 (de) | 2007-11-29 |
| DE69937368T2 true DE69937368T2 (de) | 2008-07-17 |
Family
ID=25645955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69937368T Expired - Lifetime DE69937368T2 (de) | 1998-12-21 | 1999-12-20 | Nachweis von erkrankungen der nieren und behandlung |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20020012906A1 (https=) |
| EP (1) | EP1141728B1 (https=) |
| JP (2) | JP4160263B2 (https=) |
| CN (1) | CN1331801A (https=) |
| AT (1) | ATE376187T1 (https=) |
| AU (1) | AU1674400A (https=) |
| BR (1) | BR9916407A (https=) |
| CA (1) | CA2356174A1 (https=) |
| DE (1) | DE69937368T2 (https=) |
| DK (1) | DK1141728T3 (https=) |
| IL (1) | IL143892A0 (https=) |
| MX (1) | MXPA01006404A (https=) |
| WO (1) | WO2000037944A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010038014A1 (de) * | 2010-10-06 | 2012-04-12 | Lipofit Analytic Gmbh | Verfahren zur Charakterisierung einer Probe und eines Systems |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP784398A0 (en) | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
| ATE376187T1 (de) | 1998-12-21 | 2007-11-15 | Univ Monash | Nachweis von erkrankungen der nieren und behandlung |
| US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| PT1384075E (pt) | 2001-03-28 | 2010-03-23 | Heska Corp | Métodos de detecção de doença renal inicial em animais |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
| US8603345B2 (en) * | 2003-02-13 | 2013-12-10 | Becton, Dickinson And Company | Devices for component removal during blood collection, and uses thereof |
| WO2004084841A2 (en) | 2003-03-27 | 2004-10-07 | Heska Corporation | Novel anti-feline albumin antibodies and methods of detecting early renal disease |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| WO2005016111A2 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| US20050112123A1 (en) * | 2003-10-06 | 2005-05-26 | Vaughan Michael R. | Methods of treating proteinuria |
| US20060286602A1 (en) * | 2004-05-10 | 2006-12-21 | Harald Mischak | Method and markers for the diagnosis of renal diseases |
| WO2006058278A2 (en) * | 2004-11-24 | 2006-06-01 | Hill's Pet Nutrition, Inc. | Methods for improving liver clearance of xenobiotic substances in an animal |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| US8647660B2 (en) | 2004-12-29 | 2014-02-11 | Hill's Pet Nutrition, Inc. | Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health |
| US8148325B2 (en) * | 2004-12-30 | 2012-04-03 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| BRPI0610731A2 (pt) * | 2005-04-19 | 2012-10-30 | Hills Pet Nutrition Inc | composição, método para evitar ou tratar doença do rim, conjunto para a administração de uma composição de prevenção ou tratamento de doenças do rim ao paciente, método para a promoção da saúde do rim, meios para a comunicação de informação a respeito ou instruções para a mistura e a administração de uma ou mais das composições, componentes da composição, composições alimentìcias, ingredientes alimentìcios, e drogas renais, e para a utilização de dispositivos de diagnósticos renal da presente invenção, e, uso de uma composição |
| CA2605855A1 (en) * | 2005-04-29 | 2006-11-09 | Hill's Pet Nutrition, Inc. | Methods for prolonging feline life |
| JP5289942B2 (ja) * | 2005-05-20 | 2013-09-11 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 成年動物の健康または健全を促進する方法 |
| EP1896070A4 (en) * | 2005-06-29 | 2009-04-29 | Hills Pet Nutrition Inc | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF RENAL DISEASE |
| US8492432B2 (en) * | 2005-08-17 | 2013-07-23 | Hill's Pet Nutrition, Inc. | Methods for the treatment of kidney disease |
| JP5351773B2 (ja) * | 2007-03-07 | 2013-11-27 | モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト | 尿試料中の検体の濃度を正規化するための方法 |
| EP1972940A1 (de) * | 2007-03-14 | 2008-09-24 | mosaiques diagnostics and therapeutics AG | Verfahren und Marker zur Diagnose von Nierenerkrankungen |
| US9000134B2 (en) * | 2007-05-11 | 2015-04-07 | Wallace B. Haigh | Reagent and kit for early diagnosis of kidney disease |
| WO2009047280A2 (de) * | 2007-10-09 | 2009-04-16 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptidmarker zur diagnose von prostatakrebs |
| EP2051078A1 (de) * | 2007-10-19 | 2009-04-22 | mosaiques diagnostics and therapeutics AG | Verfahren und Marker zur Diagnose von Diabetes Mellitus |
| US20120037507A9 (en) * | 2008-03-19 | 2012-02-16 | Harald Mischak | Method and marker for diagnosis of tubular kidney damage and illnesses |
| EP2313778B1 (en) | 2008-07-18 | 2015-01-28 | Boston Medical Center Corporation | Diagnostics for membranous nephropathy |
| JP2012501456A (ja) * | 2008-08-28 | 2012-01-19 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| EP2324354B1 (en) * | 2008-08-29 | 2014-07-16 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| EP2338054A1 (de) * | 2008-09-17 | 2011-06-29 | Mosaiques Diagnostics And Therapeutics AG | Nierenzellkarzinom |
| ES2836218T3 (es) | 2008-10-21 | 2021-06-24 | Astute Medical Inc | Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| CA2740923A1 (en) * | 2008-10-21 | 2010-04-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2913676A1 (en) | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2009316387B2 (en) * | 2008-11-22 | 2015-01-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2010064239A1 (en) | 2008-12-04 | 2010-06-10 | Technion Research And Development Foundation Ltd. | Apparatus and methods for diagnosing renal disorders |
| BRPI1007483B1 (pt) * | 2009-01-28 | 2021-11-30 | Bio Preventive Medicine Corporation | Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2010279249B2 (en) * | 2009-02-06 | 2015-08-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120315649A1 (en) * | 2009-08-28 | 2012-12-13 | Astute Medical ,Inc. a corporation | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ600160A (en) * | 2009-11-07 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2010315008B2 (en) | 2009-11-07 | 2015-12-03 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011075744A1 (en) | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011213684B2 (en) | 2010-02-05 | 2014-11-20 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ701807A (en) | 2010-02-26 | 2015-05-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| IN2012MN02812A (https=) | 2010-06-23 | 2015-05-22 | Astute Medical Inc | |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8930222B2 (en) * | 2010-08-05 | 2015-01-06 | Abbott Laboratories | Method and system for managing patient healthcare |
| KR101215759B1 (ko) | 2010-11-01 | 2012-12-26 | 서울대학교산학협력단 | 오로소뮤코이드를 포함하는 조성물의 용도 |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CN102854325B (zh) * | 2011-07-01 | 2015-01-07 | 复旦大学 | 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用 |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| US20130115640A1 (en) * | 2011-11-03 | 2013-05-09 | James A. Tumlin | ACTH for Treatment of Kidney Disease |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| US9689826B2 (en) | 2012-03-11 | 2017-06-27 | Technion Research And Development Foundation Ltd. | Detection of chronic kidney disease and disease progression |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP3361255B1 (en) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2016188761A (ja) * | 2013-08-23 | 2016-11-04 | 国立研究開発法人国立国際医療研究センター | 糖尿病腎症の発症または発症リスクの検出方法及びキット |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| CN104007258B (zh) * | 2013-09-30 | 2016-07-06 | 中国医学科学院基础医学研究所 | 局灶性节段性肾小球硬化的蛋白标志物 |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN104849466A (zh) * | 2014-02-14 | 2015-08-19 | 张曼 | 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用 |
| CA2955992A1 (en) * | 2014-07-23 | 2016-01-28 | University Of British Columbia | Biomarkers for anderson-fabry disease |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| US11026625B2 (en) | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CN107561175A (zh) * | 2017-08-10 | 2018-01-09 | 武汉大学 | 一种肾小球硬化大鼠模型的评价方法 |
| RU2697722C1 (ru) * | 2018-12-06 | 2019-08-19 | Ирина Сергеевна Шатохина | Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита |
| CN110632229A (zh) * | 2019-09-24 | 2019-12-31 | 华兰生物工程重庆有限公司 | 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法 |
| CN111714517A (zh) * | 2020-04-14 | 2020-09-29 | 南开大学 | 一种溶酶体作为制备药物领域的应用 |
| RU2768464C1 (ru) * | 2021-04-27 | 2022-03-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994165A (en) * | 1989-02-16 | 1991-02-19 | Cornell Research Foundation, Inc. | Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry |
| EP0514928B1 (en) * | 1991-05-24 | 1997-08-20 | Wakamoto Pharmaceutical Co., Ltd. | Method of diagnosing renal diseases by detecting albumin fragments |
| JPH0682446A (ja) * | 1992-08-31 | 1994-03-22 | Wakamoto Pharmaceut Co Ltd | 腎疾患の診断法 |
| DE4336498A1 (de) * | 1993-10-26 | 1995-04-27 | Bender & Co Gmbh | Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen |
| US5534431A (en) * | 1994-02-28 | 1996-07-09 | The Board Of Regents Of The University Of Nebraska | Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof |
| US5908925A (en) | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
| US5800998A (en) * | 1996-11-12 | 1998-09-01 | Millennium Pharmaceuticals, Inc. | Assays for diagnosing type II diabetes in a subject |
| ATE376187T1 (de) | 1998-12-21 | 2007-11-15 | Univ Monash | Nachweis von erkrankungen der nieren und behandlung |
-
1999
- 1999-12-20 AT AT99959616T patent/ATE376187T1/de not_active IP Right Cessation
- 1999-12-20 CN CN99814862A patent/CN1331801A/zh active Pending
- 1999-12-20 JP JP2000589950A patent/JP4160263B2/ja not_active Expired - Fee Related
- 1999-12-20 WO PCT/IB1999/002029 patent/WO2000037944A1/en not_active Ceased
- 1999-12-20 AU AU16744/00A patent/AU1674400A/en not_active Abandoned
- 1999-12-20 IL IL14389299A patent/IL143892A0/xx unknown
- 1999-12-20 BR BR9916407-8A patent/BR9916407A/pt not_active Application Discontinuation
- 1999-12-20 MX MXPA01006404A patent/MXPA01006404A/es not_active IP Right Cessation
- 1999-12-20 DE DE69937368T patent/DE69937368T2/de not_active Expired - Lifetime
- 1999-12-20 DK DK99959616T patent/DK1141728T3/da active
- 1999-12-20 CA CA002356174A patent/CA2356174A1/en not_active Abandoned
- 1999-12-20 EP EP99959616A patent/EP1141728B1/en not_active Expired - Lifetime
-
2001
- 2001-06-28 US US09/893,346 patent/US20020012906A1/en not_active Abandoned
- 2001-06-28 US US09/892,797 patent/US6589748B2/en not_active Expired - Fee Related
-
2003
- 2003-11-26 US US10/721,351 patent/US20040106155A1/en not_active Abandoned
-
2005
- 2005-09-16 JP JP2005270160A patent/JP4388515B2/ja not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010038014A1 (de) * | 2010-10-06 | 2012-04-12 | Lipofit Analytic Gmbh | Verfahren zur Charakterisierung einer Probe und eines Systems |
| US10497465B2 (en) | 2010-10-06 | 2019-12-03 | Numares Ag | Method for characterizing a sample by data analysis |
| DE102010038014B4 (de) | 2010-10-06 | 2021-10-07 | Numares Ag | Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1141728A4 (en) | 2005-01-12 |
| IL143892A0 (en) | 2002-04-21 |
| CA2356174A1 (en) | 2000-06-29 |
| JP4160263B2 (ja) | 2008-10-01 |
| EP1141728A1 (en) | 2001-10-10 |
| CN1331801A (zh) | 2002-01-16 |
| DE69937368D1 (de) | 2007-11-29 |
| JP2006038877A (ja) | 2006-02-09 |
| AU1674400A (en) | 2000-07-12 |
| JP4388515B2 (ja) | 2009-12-24 |
| DK1141728T3 (da) | 2008-02-04 |
| ATE376187T1 (de) | 2007-11-15 |
| US20040106155A1 (en) | 2004-06-03 |
| US20020022236A1 (en) | 2002-02-21 |
| EP1141728B1 (en) | 2007-10-17 |
| US20020012906A1 (en) | 2002-01-31 |
| WO2000037944A1 (en) | 2000-06-29 |
| US6589748B2 (en) | 2003-07-08 |
| MXPA01006404A (es) | 2003-06-06 |
| BR9916407A (pt) | 2001-09-25 |
| JP2002533680A (ja) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69937368T2 (de) | Nachweis von erkrankungen der nieren und behandlung | |
| US6447989B1 (en) | Kidney disease detection and treatment | |
| Brown et al. | Response to dexamethasone and subtype of depression | |
| DE602005002836T2 (de) | Diagnoseverfahren für erkrankungen unter verwendung von copeptin | |
| US20030003588A1 (en) | Method for kidney disease detection by protein profiling | |
| DE69429192T2 (de) | Ein verfahren zur bestimmung von kollagenfragmenten in körperflüssigkeiten, ein testkit und mittel zur durchführung des verfahrens, und seine verwendung zur feststellung von mit dem kollagenmetabolismus assoziierten störungen | |
| EP1562984B1 (de) | Sandwich-immunoassay zur bestimmung von proanp-teilpeptiden | |
| DE602004013135T2 (de) | Verfahren für die Diagnose von schwerkranken Patienten | |
| EP1564558B1 (de) | Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens | |
| DE69929785T2 (de) | Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs | |
| Rivier | Techniques for analytical testing of unconventional samples | |
| Crouthamel et al. | Specific serum quinidine assay by high-performance liquid chromatography. | |
| Psillakis et al. | Carbamazepine levels in head hair of patients under long‐term treatment: a method to evaluate the history of drug use | |
| EP2016416B1 (de) | In vitro verfahren zur erkennung und früherkennung und zur begleitenden kontrolle der therapie von arznei- und suchtmittelinduzierten leberschäden | |
| Nakamura et al. | Clinical evaluation of the liquid-chromatographic determination of urinary free cortisol. | |
| Murphy | Competitive binding to multiple stereo-specific binding agents as a means of verifying the identity of a ligand application to cortisol in human umbilical cord blood | |
| EP2097755A1 (de) | In vitro verfahren zur diagnose und frühdiagnose von neurodegenerativen erkrankungen | |
| WO2002057785A1 (de) | Verfahren zum nachweis pankreatitischer und gastrointestinaler erkrankungen | |
| DE69934236T2 (de) | Proteoglykan (azaftig) zur überwachung von kachexie und zur fettleibigkeitskontrolle | |
| Langman et al. | Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in renal transplant recipients | |
| EP0692715A1 (en) | Method of assaying for fructose-1,6-biphosphatase and diagnostic test therefrom | |
| EP0692716A1 (en) | Method of assaying for glutathione- S-transferase and diagnostic test therefrom | |
| Dias et al. | An in vitro method for assessing in vivo oral bioavailability of novel immunosuppressive drugs | |
| Langman et al. | Distribution of a new immunosuppressive drug mucophenolic acid in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NIPRO CORP., OSAKA, JP |